A Florida circuit court judge refused to throw out the state's $350 million lawsuit against Planned Parenthood, ruling Tuesday that the case over the organization's marketing of the abortion pill can proceed to trial. The decision keeps alive one of the most aggressive state-level legal challenges to Planned Parenthood's advertising practices in recent memory.

First Circuit Court Judge J. Scott Duncan, sitting in Santa Rosa County, struck down Planned Parenthood's motion to dismiss the suit, which alleges the organization ran a deceptive campaign telling women that the chemical abortion drug mifepristone is "safer than Tylenol." Florida Attorney General James Uthmeier filed the lawsuit in November 2025, and the ruling means Planned Parenthood will now have to defend those claims in open court.

The stakes are substantial, both in dollar terms and in what the case could mean for how abortion providers market their services. And the fact that Planned Parenthood tried to kill the lawsuit before discovery even began, and failed, tells you something about the strength of the state's complaint.

The lawsuit: RICO, racketeering, and a $350 million price tag

Uthmeier's office didn't file a garden-variety consumer-protection complaint. Fox News reported that the suit invokes Florida's RICO statutes, racketeering laws more commonly associated with organized crime, alleging that Planned Parenthood engaged in a pattern of deceptive activity designed to funnel vulnerable women toward profitable chemical abortions.

The core allegation is straightforward: Planned Parenthood told women that mifepristone is safer than Tylenol, Viagra, and penicillin. Florida says that claim is false and dangerous.

Uthmeier put it bluntly when the suit was filed: "Planned Parenthood sells profitable abortions to vulnerable women by lying to them about abortion pills being safer than Tylenol." The state's filing added that the "use of chemical abortion drugs routinely lands women in the emergency room with hemorrhaging and other serious complications."

Florida's complaint cites data indicating that approximately 10 percent of women who undergo chemical abortion experience septic conditions or life-threatening side effects within 45 days. That figure, if borne out in court, would make the "safer than Tylenol" pitch look less like marketing puffery and more like a deliberate misrepresentation of medical risk.

Planned Parenthood's failed bid to end the case early

Planned Parenthood moved to dismiss the suit, a standard legal maneuver that asks the court to rule the complaint is too weak to proceed even before evidence is exchanged. Judge Duncan disagreed. His May 27 order, as reported by the Catholic News Agency, keeps the case alive and sets the stage for discovery, depositions, and potentially a trial.

The ruling itself does not resolve the merits. It does not declare that Planned Parenthood lied. But it means a Florida judge looked at the state's allegations and found them plausible enough to warrant a full hearing. That alone is a significant setback for an organization accustomed to operating with minimal legal accountability over its advertising.

Planned Parenthood has not publicly responded to the ruling, at least not in any statement captured in available reporting. The organization's silence is notable. When you're facing a $350 million RICO suit and a judge just told you the case has legs, you'd expect a vigorous public defense, unless you're saving your arguments for the courtroom.

A pattern of legal setbacks for the abortion industry

The Florida ruling lands in the middle of a broader legal landscape that has shifted markedly against abortion providers and their allies in recent years. Courts at every level have shown a growing willingness to hold the industry to the same standards applied to any other business making health claims to consumers.

The Fifth Circuit's decision to halt an FDA rule allowing mail-order abortion pills reflected similar concerns about chemical abortion safety and regulatory permissiveness. In that case, the court sided with states arguing that federal regulators had loosened safeguards without adequate justification.

Meanwhile, the Supreme Court has moved to give states more authority over abortion-related policy. The high court's recent decision empowering states to cut Planned Parenthood from Medicaid signaled that the judiciary is no longer treating the organization as a protected class exempt from the rules that govern every other healthcare provider.

And the trend extends beyond abortion-specific cases. A federal judge struck down an Oregon law that tried to force a pro-life organization to fund abortion coverage, another instance of the courts drawing a line against government overreach on reproductive policy.

Why the "safer than Tylenol" claim matters

The marketing comparison at the center of Florida's lawsuit is not some obscure footnote in Planned Parenthood's communications. It has been a central talking point deployed nationally to reassure women considering chemical abortion. The pitch is designed to make mifepristone sound as routine as popping an over-the-counter painkiller.

But Tylenol doesn't carry a risk of hemorrhaging. Tylenol doesn't send roughly one in ten users to the emergency room within six weeks. And Tylenol isn't prescribed through a process that, critics argue, often minimizes informed consent about potential complications.

Florida's case rests on the premise that consumers deserve honest information about medical products, especially when the stakes involve a woman's health. If a pharmaceutical company told patients its drug was safer than aspirin while knowing that a significant percentage of users experienced serious adverse events, no one would hesitate to call that false advertising. The state is asking why Planned Parenthood should be held to a different standard.

Breitbart reported on the original filing in November 2025, noting the breadth of the state's claims and the unusual use of RICO authority against an abortion provider. The legal theory is aggressive, but it reflects a broader argument that organizations like Planned Parenthood have operated for decades behind a shield of political sympathy that insulated them from the kind of consumer-protection scrutiny applied to every other industry.

What comes next

With the motion to dismiss denied, the lawsuit enters its next phase. Discovery will likely force Planned Parenthood to turn over internal communications, marketing materials, and data about patient outcomes related to mifepristone. For an organization that has long resisted transparency, that process alone could prove revealing.

The legal fight also carries political weight. Pro-life advocates have scored a string of courtroom wins in recent years, from Mark Houck's seven-figure settlement with the DOJ after a botched FBI raid to state-level victories that have reshaped the regulatory environment around abortion. Florida's case adds another front, this time targeting not the procedure itself but the way it is sold to women.

Several questions remain unanswered. What specific grounds did Judge Duncan rely on in refusing to dismiss? Will Planned Parenthood seek an interlocutory appeal? And will other state attorneys general follow Florida's lead and file their own false-advertising complaints?

None of that is settled yet. What is settled is that Planned Parenthood asked a court to make this case go away, and the court said no.

When an organization has to answer in court for telling women a drug is as safe as Tylenol, while the state says the evidence shows otherwise, that's not a political attack. That's accountability. And it's long overdue.